Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 11
Submit an article Journal homepage
424
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients

Blanca Boludaa Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain;b Instituto de Investigación Sanitaria La Fe, Valencia, SpainORCID Iconhttps://orcid.org/0000-0002-1785-5561View further author information
ORCID Icon,
David Martínez-Cuadróna Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain;b Instituto de Investigación Sanitaria La Fe, Valencia, SpainORCID Iconhttps://orcid.org/0000-0001-7540-4091View further author information
ORCID Icon,
Lorenzo Algarrac Hematology Department, Complejo Hospitalario Universitario de Albacete, Albacete, SpainView further author information
,
Isabel Canoa Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain;b Instituto de Investigación Sanitaria La Fe, Valencia, SpainView further author information
,
María J. Sayasd Hematology Department, Hospital Doctor Peset, Valencia, SpainView further author information
,
Evelyn Acuña-Cruza Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain;b Instituto de Investigación Sanitaria La Fe, Valencia, SpainView further author information
,
Albert Blancoa Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, SpainView further author information
,
Javier Marco-Ayalaa Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, SpainView further author information
,
Rosalía DeLapuertaa Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, SpainView further author information
,
Álvaro Díaz-Gonzáleza Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, SpainView further author information
,
Mar Tormoe Hematology Department, Hospital Clínico Universitario, Valencia, SpainORCID Iconhttps://orcid.org/0000-0001-9622-1649View further author information
ORCID Icon,
Rebeca Rodríguez-Veigaa Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain;b Instituto de Investigación Sanitaria La Fe, Valencia, SpainORCID Iconhttps://orcid.org/0000-0003-2139-8540View further author information
ORCID Icon,
Raimundo Garcíaf Hematology Department, Hospital General Castellón, Castellón, SpainView further author information
,
José L. Piñanaa Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain;b Instituto de Investigación Sanitaria La Fe, Valencia, SpainORCID Iconhttps://orcid.org/0000-0001-8533-2562View further author information
ORCID Icon,
María López-Pavíag Hematology Department, Hospital General Universitario, Valencia, SpainView further author information
,
Eva Barragána Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain;b Instituto de Investigación Sanitaria La Fe, Valencia, SpainView further author information
,
María L. Amigoh Hematology Department, Hospital Morales Meseguer, Murcia, SpainView further author information
,
Claudia Sargasa Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain;b Instituto de Investigación Sanitaria La Fe, Valencia, SpainView further author information
,
Aurelio Lópezi Hematology Department, Hospital Arnau de Vilanova, Valencia, SpainView further author information
,
Antonio Solana-Altabellab Instituto de Investigación Sanitaria La Fe, Valencia, Spain;j Pharmacy Department, Hospital Universitari i Politècnic La Fe, Valencia, SpainORCID Iconhttps://orcid.org/0000-0002-8804-3878View further author information
ORCID Icon,
Cristina Gilk Hematology Department, Hospital General Universitario de Alicante, Alicante, SpainORCID Iconhttps://orcid.org/0000-0002-5062-2364View further author information
ORCID Icon,
Juan Eduardo Megías-Vericatb Instituto de Investigación Sanitaria La Fe, Valencia, Spain;j Pharmacy Department, Hospital Universitari i Politècnic La Fe, Valencia, SpainORCID Iconhttps://orcid.org/0000-0002-0369-5341View further author information
ORCID Icon,
Miguel A. Sanza Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain;b Instituto de Investigación Sanitaria La Fe, Valencia, SpainORCID Iconhttps://orcid.org/0000-0003-1489-1177View further author information
ORCID Icon &
Pau Montesinosa Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain;b Instituto de Investigación Sanitaria La Fe, Valencia, SpainCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-3275-5593View further author information
ORCID Icon show all
Pages 2727-2736 | Received 21 Apr 2021, Accepted 26 May 2021, Published online: 14 Jun 2021

References

  • Lim SH, Dubielecka PM, Raghunathan VM. Molecular targeting in acute myeloid leukemia. J Transl Med. 2017;15(1):183.
  • Megías-Vericat JE, Martínez-Cuadrón D, Sanz MÁ, et al. Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review. Ann Hematol. 2018;97(7):1115–1153.
  • Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
  • Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–2221.
  • Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia. 1996;10(12):1911–1918.
  • Smith CC, Wang Q, Chin C-S, et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature. 2012;485(7397):260–263.
  • Ravandi F, Kantarjian H, Faderl S, et al. Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. Leuk Res. 2010;34(6):752–756.
  • Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381(18):1728–1740.
  • Cortes JE, Khaled S, Martinelli G, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):984–997.
  • Vardiman J S, Swerdlow SH, Campo E, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: World Heal. Organ. Calssification Tumours Haematop. Lymphoid Tissue; 2008.
  • Döhner H, Estey EH, Amadori S, et al.; European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453–474.
  • Bertoli S, Dumas P, Emilie B, et al. Outcome of relapsed or refractory FLT3 -mutated acute myeloid leukemia before second-generation FLT3 tyrosine kinase inhibitors: A. Cancers. 2020;12(4):773–712.
  • Nagel G, Weber D, Fromm E, et al.; German-Austrian AML Study Group (AMLSG). Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO). Ann Hematol. 2017;96(12):1993–2003.
  • Martínez-Cuadrón D, Serrano J, Gil C, et al. Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing? Leukemia. 2020;35(6):1571–1585.
  • Cocciardi S, Dolnik A, Kapp-Schwoerer S, et al. Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation. Nat Commun. 2019;10(1):2031.
  • Bergua JM, Montesinos P, Martinez-Cuadrón D, et al.; the PETHEMA group. A prognostic model for survival after salvage treatment with FLAG-Ida +/− gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia. Br J Haematol. 2016;174(5):700–710.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.